Medindia

X

Axillary Hyperhidrosis Therapeutics Pipeline Industry Review H1 2016 Research Report

Wednesday, May 18, 2016 Research News J E 4
Advertisement
Wiseguyreports.com add report on "Axillary Hyperhidrosis - Pipeline Review, H1 2016" new report to its research database. The report spread across 55 pages with table and figures.

PUNE, India, May 18, 2016 /PRNewswire-iReach/ -- The report "Axillary Hyperhidrosis - Pipeline Review, H1 2016" provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects.

Photo - http://photos.prnewswire.com/prnh/20160518/369104

Get Complete Report Details @ https://www.wiseguyreports.com/reports/axillary-hyperhidrosis-pipeline-review-h1-2016 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Involved in Axillary Hyperhidrosis Therapeutics Development:

  • Allergan Plc
  • Brickell Biotech, Inc.
  • Dermira Inc.
  • GlaxoSmithKline Plc
  • Revance Therapeutics, Inc.
  • TheraVida, Inc.

Drug Profiles discussed in this report includes: (oxybutynin chloride + pilocarpine hydrochloride), ANT-1207, ANT-1403, daxibotulinumtoxin A, DRM-04, oxybutynin chloride, sofpironium bromide, umeclidinium bromide.

Purchase a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=469362 .

Featured News & Press Releases included in this report:

  • Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
  • Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
  • Jan 07, 2016: Dermira Provides DRM04 Development Program Update
  • Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
  • Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
  • Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines
  • Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
  • Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
  • Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
  • Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis

Scope of this report includes:

- The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis - The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects - The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis

Request a sample copy@ https://www.wiseguyreports.com/sample-request/axillary-hyperhidrosis-pipeline-review-h1-2016 .

Contact for More Information at sales@wiseguyreports.com or +1 (646) 845 9349 (US) and +44 208 133 9349 (UK)

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349, sales@wiseguyreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE WiseGuy Reports

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Canadian Journal of Infection Control to Publish P...
S
Major Depressive Disorder Therapeutics Pipeline In...